Bioprojet

5 articles about Bioprojet

• Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant)

  10/28/2020

  Citrine was founded by Eight Roads, F-Prime Capital, and Vivo Capital; and closed an $80 Million Series A financing earlier this year Company is focused on bringing important rare disease therapies to China while accelerating the rare disease drug development process worldwide Wakix® will address high unmet medical need for the treatment of people with narcolepsy in China

• Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada

  7/25/2018

  Agreement to register, commercialize, and distribute pitolisant on an exclusive basis in Canada.

• 

  Harmony Biosciences Makes Headway on Narcolepsy Drug Involving Histamine

  6/22/2018

  For type 1 narcolepsy, this sleep-wake instability is linked to low levels of hypocretin, also called orexin. Hypocretin is a neurotransmitter produced in the hypothalamus and has a significant role in wakefulness and regulating rapid eye movement (REM) sleep. But Harmony Biosciences has found an...

• Pinnacle Biologics Announces Appointment of Bioprojet as Exclusive Distributor in Select European Countries

  4/19/2012

• DBV Technologies and Bioprojet Enter Into Distribution Agreement For Diallertest(R) Milk

  10/12/2009